AI research biotech Earendil Labs has penned a $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates (ADCs). | AI research biotech Earendil Labs has penned a $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates (ADCs).Read More
Earendil pens $885M pact to use WuXi XDC’s linker tech for next-gen ADCs
